Monday May 29th 2017

MS Trial Alert: Recruitment for Study of Plovamer Acetate vs. Copaxone in Relapsing-Remitting MS

Summary: Investigators are recruiting approximately 550 people with relapsing-remitting MS worldwide for a study to determine the effectiveness, safety and tolerability of four doses of plovamer acetate versus Copaxone® (glatiramer acetate, Teva Pharmaceutical Industries, Ltd.). The study is funded by EMD Serono.

Link to article: 

MS Trial Alert: Recruitment for Study of Plovamer Acetate vs. Copaxone in Relapsing-Remitting MS

Leave a Comment

More from category

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]

Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS
Brain Gadolinium Deposition Varies With Contrast Agent in MS Brain Gadolinium Deposition Varies With Contrast Agent in MS

Gadolinium accumulation in the brain is greater with linear GBCAs than with macrocyclics. Multiple sclerosis experts [Read More]